Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL378898 | 1.00 | — | — | |
| Bicarbonate SCHEMBL853 | 1.00 | — | — | |
| Bicarbonate SCHEMBL4268006 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL2718215 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL10746789 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL5458673 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL8535954 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL8531740 | 1.00 | CA1 (0.83) | — | |
| Bicarbonate SCHEMBL21405704 | 1.00 | — | — | |
| Bicarbonate SCHEMBL538566 | 1.00 | CA1 (0.83) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250092065-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-20240368163-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12043607-B2 | HDAC inhibitors and therapeutic use thereof | TANGO THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4396177-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20150126485-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| EP-2861576-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| EP-2858988-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| CN-104379574-A | Benzamide derivatives for inhibiting the activity of ABL1, ABL 2 and BCR-ABL 1 | NOVARTIS AG | 2015-02-25 | — | — | CN | disclosed |
| CN-104302634-A | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG | 2015-01-21 | — | — | CN | disclosed |
| WO-2013171642-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013171640-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| US-20070099938-A1 | Antistress drug and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1679309-A1 | ANTISTRESS DRUG AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| EP-0254596-B1 | MANUFACTURING METHOD FOR 2-HYDROXYNAPHTALENE-6-CARBOXYLIC ACID | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 1993-02-10 | — | — | EP | disclosed |